Trial Profile
Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV, on Stable Treatment, and Virologically Suppressed for at Least 6 Months
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 20 Aug 2021 New trial record